共 25 条
Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
被引:151
作者:
Cowen, Edward W.
[1
]
Nguyen, Josephine C.
[1
]
Miller, Daniel D.
[2
]
McShane, Diana
[3
]
Arron, Sarah T.
[2
]
Prose, Neil S.
[3
]
Turner, Maria L.
[1
]
Fox, Lindy P.
[2
]
机构:
[1] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
[3] Duke Univ, Dept Dermatol, Durham, NC 27706 USA
基金:
美国国家卫生研究院;
关键词:
fungal infection;
immunosuppression;
photoaging;
photosensitivity;
phototoxicity;
squamous cell carcinoma;
voriconazole;
TRANSPLANT RECIPIENTS;
ANTIFUNGAL AGENT;
THERAPY;
CANCERS;
PSEUDOPORPHYRIA;
PATIENT;
D O I:
10.1016/j.jaad.2009.09.033
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100227 [皮肤病学];
摘要:
Background. Voriconazole is a broad-spectrum antifungal agent associated with photosensitivity and accelerated photoaging. A possible link with aggressive squamous cell carcinoma (SCC) has also been reported. Objective: We sought to determine the incidence and frequency of cutaneous SCC among patients undergoing long-term treatment with voriconazole who also manifest features of chronic phototoxicity. Methods: We conducted a retrospective review of patients who developed one or more squamous cell neoplasms during long-term treatment with voriconazole at 3 academic dermatology centers. Results: A total of 51 cutaneous SCC were identified in 8 patients (median age 34.5 years, range 9-54) treated with chronic voriconazole (median duration 46.5 months, range 13-60). Underlying diagnoses included graft-versus-host disease, HIV, and Wegener granulomatosis. Signs of chronic phototoxicity and accelerated photoaging included erythema, actinic keratoses, and lentigo formation. Limitations: The retrospective nature of the study cannot determine the true population risk of SCC associated with voriconazole therapy. A prospective cohort study is needed. Conclusion: A high index of suspicion for photosensitivity and SCC may be warranted with chronic voriconazole use when used in the setting of concurrent immunosuppression. (J Am Acad Dermatol 2010;62:31-7.)
引用
收藏
页码:31 / 37
页数:7
相关论文

